We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

22 hedge funds and large institutions have $340K invested in NeuBase Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

13% more capital invested

Capital invested by funds: $301K → $340K (+$39K)

5% more funds holding

Funds holding: 21 → 22 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
3
Increased
3
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$47.9K
2
Renaissance Technologies
Renaissance Technologies
New York
+$41.6K
3
Two Sigma Investments
Two Sigma Investments
New York
+$15.4K
4
TRCT
Tower Research Capital (TRC)
New York
+$12
5
Wells Fargo
Wells Fargo
California
+$10

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$10.7K
2
KAS
Kestra Advisory Services
Texas
-$1.09K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$264
4
BlackRock
BlackRock
New York
-$260
5
First Manhattan
First Manhattan
New York
-$257
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$101K – – –
UBS Group
2
UBS Group
Switzerland
$48.6K +$47.9K +65,724 New
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$46.3K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$42K +$41.6K +56,967 New
CMU
5
Carnegie Mellon University
Pennsylvania
$34.8K – – –
Two Sigma Investments
6
Two Sigma Investments
New York
$15.6K +$15.4K +21,083 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$14K – – –
KAS
8
Kestra Advisory Services
Texas
$12.2K -$1.09K -1,500 -8%
PCM
9
Prelude Capital Management
New York
$11.5K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$11.5K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$1.81K +$12 +16 +0.7%
Bank of America
12
Bank of America
North Carolina
$595 – – –
First Manhattan
13
First Manhattan
New York
$261 -$257 -353 -50%
BlackRock
14
BlackRock
New York
$62 -$260 -356 -81%
Wells Fargo
15
Wells Fargo
California
$58 +$10 +14 +22%
Osaic Holdings
16
Osaic Holdings
Arizona
$16 – – –
PNC Financial Services Group
17
PNC Financial Services Group
Pennsylvania
$16 – – –
Morgan Stanley
18
Morgan Stanley
New York
$12 +$7 +9 +100%
GWMIA
19
Global Wealth Management Investment Advisory
Florida
$9 – – –
NFSG
20
Newbridge Financial Services Group
Florida
$9 – – –
TSS
21
Two Sigma Securities
New York
– -$10.7K -12,354 Closed
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
– -$264 -362 -55%

NBSE Hedge Fund Activity: Q4 2023 in Review

22 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2023, worth a combined $340K — up 13% from $301K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new NBSE positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $47.9K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $10.7K sold.

  • 22 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2023, up from 21 in Q3 2023.
  • Funds reported $340K of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2023, up 13% quarter-over-quarter.
  • 3 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2023 and 1 closed out, a net change of +2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2023 was UBS Group, an estimated $47.9K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2023 was Two Sigma Securities, an estimated $10.7K sold.

Based on aggregated 13F filings for Q4 2023.